Abstract:Dear Editor, It was proposed by Haider and Ashraf1 that cytokine and growth factor mediated mobilization of endogenous mesenchymal stem cells from their bone marrow niches for homing into the infarcted myocardium could be a better therapeutic strategy than the explantation and subsequent injection of these cells (either autologous or from a donated allogenic source) directly into the damaged heart.2 Besides being less invasive to the patient, it was argued that this approach would obviate the need for ex vivo processing of the putative stem cells, which could in turn reduce the risk of nonspecific differentiation into undesired lineages at the transplantation site.3–5 Nevertheless, such an approach could be severely hampered by the age related decline in the regenerative capacity of the putative mesenchymal stem cell population within the bone marrow, as has been demonstrated by a number of studies.6,7 It must be remembered that the overwhelming majority of myocardial infarct cases occur in the older segment of the population.8 Quarto and colleagues6 demonstrated in a rat model that there was an age associated decline in the ability of marrow stromal cells to repair bone, which could be the underlying cause of age related osteodegenerative diseases. Subsequently, D’Ippolito and colleagues7 reported a similar finding with the human model. This would be expected because, with increasing age, the putative mesenchymal stem cell population within the bone marrow would have gone through more rounds of cell division, in addition to having been exposed to free radicals and metabolic toxins over a longer lifespan. Hence it is no surprise that there is a gradual decline in their regenerative capacity with increasing age. Although there have been no studies to date that have conclusively demonstrated an age associated decline in the capacity of bone marrow cells to repair the infarcted heart, we could make such a conjecture based upon extrapolation from the bone repair model.6,7 The obvious solution to overcome this age related decline in regenerative capacity would be to look at donated allogenic sources of stem cells for myocardial repair. In this regard, human embryonic stem (hES) cells or their differentiated progenies would hold much promise because these potentially represent an abundant and readily available source of transplantable cells. Recently, Zandstra and colleagues9 successfully developed a scalable, robust, and reproducible process for obtaining purified cardiomyocytes from hES cells. Nevertheless, the immunologic barrier10 probably represents the most formidable challenge to the allogenic transplantation of hES cells or their differentiated progenies into the infarcted myocardium. It is hoped that this could somehow be overcome in the near future. Boon Chin Heng* Eugene Kwang-Wei Sim† Tong Cao* *Stem Cell Laboratory, Faculty of Dentistry, †Department of Surgery, Faculty of Medicine National University of Singapore.

Stem cell therapy in the aging hearts of Fisher 344 rats: Synergistic effects on myogenesis and angiogenesis

Reply to Letter from Drs. Haider and Ashraf

Homing of intravenously infused embryonic stem cell- derived cells to injured hearts after myocardial infarction

Therapeutic angiogenesis by transplantation of human embryonic stem cell-derived CD133+ endothelial progenitor cells for cardiac repair.

Intravenous Administration of Embryonic Stem Cells Home into Injured Hearts and Improve Cardiac Function Post Myocardial Infarction in Rats

Antiapoptotic Effect of Implanted Embryonic Stem Cell-Derived Early-Differentiated Cells in Aging Rats after Myocardial Infarction.

Abstract 9586: Existence of Small Juvenile Cells in the Aging Bone Marrow Stromal Cells and Their Therapeutic Potential for Ischemic Heart Disease

Transplantation of Embryonic Stem Cells Improves Cardiac Function in Postinfarcted Rats

Advanced Age Impairs Cardioprotective Function of Mesenchymal Stem Cell Transplantation from Patients to Myocardially Infarcted Rats

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

Transplantation of SIRT1-engineered aged mesenchymal stem cells improves cardiac function in a rat myocardial infarction model.

Characterization of rat very small embryonic-like stem cells and cardiac repair after cell transplantation for myocardial infarction.

Small extracellular vesicles from young adipose-derived stem cells ameliorate age-related changes in the heart of old mice.

Cell therapy rescues aging-induced beta-1 adrenergic receptor and GRK2 dysfunction in the coronary microcirculation

Effect of Transplanted Mesenchymal Stem Cells from Rats of Different Ages on the Improvement of Heart Function after Acute Myocardial Infarction

Effect of donor rat age on the angiogenesis of acute myocardial infarction rats following mesenchymal stem cell transplantation

Stem cells for heart failure in the aging heart

Injectable Biodegradable Hydrogels for Embryonic Stem Cell Transplantation: Improved Cardiac Remodelling and Function of Myocardial Infarction

Both the Transplantation of Somatic Cell Nuclear Transfer- and Fertilization-Derived Mouse Embryonic Stem Cells with Temperature-Responsive Chitosan Hydrogel Improve Myocardial Performance in Infarcted Rat Hearts.

Paracrine IGF-1 Activates SOD2 Expression and Regulates ROS/p53 Axis in the Treatment of Cardiac Damage in D-Galactose-Induced Aging Rats after Receiving Mesenchymal Stem Cells

Improvements of cardiac electrophysiologic stability and ventricular fibrillation threshold in rats with myocardial infarction treated with cardiac stem cells.